解毒通络合剂对冠心病PCI患者MMP-9、ET-1、NO、hs-CRP的影响  

The effect of Jiedutongluo Mixture on PCI,ET-1,NO,hs-CRP of Patients with Coronary Heart Disease

作　　者：魏陵博 辛辉[2] 戎冬梅 钟志欢 吉中强 迟玉萍[3] 

机构地区：[1]山东省青岛市海慈医疗集团,山东青岛266033 [2]青岛大学医学院附属医院,山东青岛266003 [3]山东中医药大学,山东济南250014

出　　处：《中国中医急症》2012年第12期1895-1896,1906,共3页Journal of Emergency in Traditional Chinese Medicine

基　　金：山东省中医药科技发展计划项目(2009-2010年度)(2009-198)

摘　　要：目的观察解毒通络合剂对冠心病PCI术后患者基质金属蛋白酶-9(MMP-9)、内皮素-1(ET-1)、一氧化氮(NO)、超敏C反应蛋白(hs-CRP)的影响。方法将90例冠心病PCI术后成功患者随机分为治疗组和对照组各45例,对照组给予安慰剂;治疗组以解毒通络合剂口服,疗程4周。结果治疗组MMP-9、ET-1、hs-CRP含量较对照组明显降低,NO含量较对照组明显提高。结论解毒通络法可以防治冠心病心脏冠状动脉内支架(PCI)术后再狭窄。Objective： To observe the effect of Jiedutongluo mixture on matrix metalloproteinase-9（MMP-9）,endothelin-1（ET-1）,nitric oxide（NO）,high-sensitivity C-reactive protein（hs-CRP） of patients with coronary heart disease after PCI.Methods： Successful patients of the 90 patients with coronary heart disease after PCI were randomly divided into treatment group and control group,both with the number of 45.the control group were given a placebo;treatment group were given JieDuTongLuo Mixture orally;and the course of treatment was 4 weeks.Results： the test group of MMP-9,ET-1,hsCRP levels compared with the control group significantly decreased NO content compared with the control group improved significantly.Conclusion： JieDuTongLuo mixture act prevention of coronary heart disease restenosis after PCI.

关 键 词：解毒通络合剂 PCI术后 MMP-9 ET-1 NO HS-CRP 

分 类 号：R541.4[医药卫生—心血管疾病]